title: Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia.
abstract: OBJECTIVE
  There is discussion about the effect of cholinesterase inhibitors (CERs) on weight of patients with Alzheimer's disease (AD). Given the adverse outcomes of weight loss in AD patients, it is important to establish the effect of CERs on weight. This study aimed tot assess the long-term effect of galantamine on weight of AD patients.
  
  
  METHODS
  This longitudinal study was performed at a large memory clinic in the North of the Netherlands. During the period 2002 to 2010, 303 community-dwelling AD patients, aged 65 years or older who started using a cholinesterase inhibitor (CER), were included.
  
  
  METHODS
  Socio-demographic characteristics and data on comorbidity, number of medications, type and dosage of CER, use of care, cognitive function, behaviour and nutritional status (weight, Body Mass Index (BMI)) were recorded at the time the diagnosis AD was made and at subsequent outpatient clinic visits. The Generalized Estimating Equations (GEE) model was used to determine the effect of galantamine of 16 mg and 24 mg on weight. The effect of galantamine in a dose of 16 and 24 mg was investigated because the other groups (rivastigmine, galantamine 8 mg) were too small to determine the effect on weight by GEE analysis. Donepezil is not available in the Netherlands.
  
  
  RESULTS
  The median follow-up time between the moment patients started using a CER (T0) and the 1st visit was 6 months (n=300); between T0 and the 2nd visit 13 months (n=212); between T0 and the 3rd visit 25 months (n=117) and between T0 and the 4th visit 37 months (n=58). Galantamine 16 mg and 24 mg, corrected for age, gender, social status, informal care, professional care, comorbidity, number of medications, cognition, behaviour and appetite, had no effect on weight (p > 0.05). Male patients had a higher average weight compared to female patients (p=0.000, B=8.333). Patients without an informal caregiver (p=0.01, B=-3.697) or partner (p=0.042, B=-3.197) had a lower average weight compared to patients with an informal caregiver or partner.
  
  
  CONCLUSIONS
  Weight loss in AD patients should not be attributed to long-term treatment with galantamine. This is in accordance with the French guideline. If AD patients are losing weight, other causes, including insufficient care, should be investigated.
authors: Geriatric Medicine, Medical Centre Leeuwarden, Po Box 888 Leeuwarden 8901 BR, The Netherlands.
authors: E
authors: E
authors: Droogsma
authors: D Z B
authors: DZ
authors: van Asselt
authors: J H M
authors: JH
authors: van Steijn
authors: T
authors: T
authors: Schuur
authors: E J
authors: EJ
authors: Huinink
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D001835:Body Weight / Q000187:drug effects*; D017028:Caregivers; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005702:Galantamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009426:Netherlands; D012189:Retrospective Studies; D012737:Sex Factors; D015431:Weight Loss
chemical_list: D002800:Cholinesterase Inhibitors; D005702:Galantamine
references: Biometrics. 1986 Mar;42(1):121-30
references: 3719049
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: CNS Drugs. 2010 May;24(5):431-42
references: 20369907
references: Am J Clin Nutr. 2000 Feb;71(2):637S-642S
references: 10681272
references: J Gerontol A Biol Sci Med Sci. 2006 May;61(5):516-20
references: 16720751
references: J Nutr Health Aging. 2007 Jan-Feb;11(1):33-7
references: 17315078
references: Clin Nutr. 2009 Apr;28(2):141-6
references: 19232792
references: Dement Geriatr Cogn Disord. 2009;28(5):389-403
references: 19893314
references: Neurology. 1984 Jul;34(7):939-44
references: 6610841
references: J Am Geriatr Soc. 2008 Oct;56(10):1926-31
references: 18811613
references: Neurology. 2000 Jun 27;54(12):2269-76
references: 10881251
references: Neurology. 2000 Jun 27;54(12):2261-8
references: 10881250
references: J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):310-4
references: 11861686
references: Aging Ment Health. 2010 May;14(4):481-8
references: 20455124
references: J Nutr Health Aging. 2007 Jan-Feb;11(1):38-48
references: 17315079
references: Age Ageing. 2005 Mar;34(2):136-41
references: 15644407
references: J Am Geriatr Soc. 1998 Oct;46(10):1223-7
references: 9777903
references: Stat Med. 2000 Jun 15-30;19(11-12):1401-9
references: 10844705
references: J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):59-65
references: 10369823
references: Curr Neuropharmacol. 2010 Mar;8(1):69-80
references: 20808547
references: J Am Geriatr Soc. 2012 Apr;60(4):805-6
references: 22494299
references: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593
references: 16437532
references: J Nutr Health Aging. 2005;9(2):69-73
references: 15791348
references: Am J Clin Nutr. 2005 Aug;82(2):435-41
references: 16087990